Rznomics has published optimized methods for manufacturing circular RNA with up to two-fold higher efficiency for longer sequences, achieved through systematic target-site selection and construct engineering. This advancement addresses a critical manufacturing bottleneck that has limited the scalability and therapeutic range of circular RNA platforms for vaccines and gene therapies.
Key Points
- Two-fold efficiency gain for circular RNA synthesis of ~8 kilobase sequences
- Self-Targeting and Splicing method eliminates extraneous sequences, reducing immunogenicity
- Scalable manufacturing across wider range of RNA lengths now feasible
Longevity Analysis
Circular RNA has emerged as a more stable and immunologically favorable alternative to linear RNA for therapeutic delivery, with direct implications for vaccine durability and sustained gene therapy efficacy. This manufacturing advancement removes a practical constraint that has prevented broader clinical translation—efficiency gains at scale determine whether these therapies can reach patients and sustain immune function over time. The elimination of extraneous sequences also reduces unwanted immune activation, which is critical for therapies intended to support rather than overwhelm the body's defense mechanisms.
Original published by LT Wire.